A 12-Week, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Anti-Inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Losmapimod (Primary) ; Salmeterol/fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 19 Apr 2012 Planned number of patients changed from 300 to 740 as reported by European Clinical Trials Database.
- 19 Feb 2010 Actual patient number (306) added as reported by ClinicalTrials.gov.